For the Inventor, By the Inventor

Enter assignee name

Seattle, WA, United States of America

Neorx Corporation

Calculating rank

USPTO Granted Patents = 156

% Expired Patents = 8.3

CIPO Patents = 1

Forward Citations = 6,558

Loading Chart...

Loading Chart...

69 inventors (with patents filed for the assignee):

Alan R Fritzberg (44 out of 53 patents)

Sudhakar Kasina (38 out of 50 patents)

John M Reno (36 out of 45 patents)

4. Ananthachari Srinivasan (33 out of 48 patents)

5. David John Grainger (20 out of 42 patents)

6. Linda M Gustavson (20 out of 32 patents)

7. James C Metcalfe (18 out of 20 patents)

8. Louis J Theodore (17 out of 23 patents)

9. Paul G Abrams (15 out of 19 patents)

10. Lawrence L Kunz (15 out of 17 patents)

11. Donald B Axworthy (13 out of 15 patents)

12. Daniel S Wilbur (13 out of 13 patents)

13. Peter L Weissberg (12 out of 13 patents)

14. Mark D Hylarides (9 out of 12 patents)

15. A Charles Morgan, Jr (9 out of 15 patents)

Core Competencies:

Radiolabeled Annexins

Radionuclide Complexes

Targeting Protein-Diagnostic Conjugates

Therapeutic Inhibitors

Pretargeting Methods

Cardiovascular Pathologies

Biotin-DOTA Conjugates

Aromatic Amine Ligands

Hepatic-Directed Compounds

Nitro-Benzyl-DOTA

Small Molecular Weight Ligands

Chelating Compounds

156 patents: Sort by Forward Citations

1. 7115720 - Therapeutic and diagnostic compounds, compositions, and methods (2006-10-03),

2. 7115248 - Radiolabeled annexins (2006-10-03),

3. 7097823 - High dose radionuclide complexes for bone marrow suppression (2006-08-29),

4. 7094885 - Skeletal-targeted radiation to treat bone-associated pathologies (2006-08-22),

5. 7094550 - Method to determine TGF-beta (2006-08-22),

6. 7084171 - Compounds and therapies for the prevention of vascular and non-vascular pathologies (2006-08-01),

7. 7070759 - High dose radionuclide complexes for bone marrow suppression (2006-07-04),

8. 6936700 - Bridged aromatic substituted amine ligands with donor atoms (2005-08-30),

9. 6767531 - High dose radionuclide complexes for bone marrow suppression (2004-07-27),

10. 6734208 - Compounds and therapies for the prevention of vascular and non-vascular pathologies (2004-05-11),

11. 6709652 - Pretargeting methods and compounds (2004-03-23),

12. 6663881 - Therapeutic inhibitor of vascular smooth muscle cells (2003-12-16),

13. 6599928 - Therapeutic inhibitor of vascular smooth muscle cells (2003-07-29),

14. 6569441 - Therapeutic inhibitor of vascular smooth muscle cells (2003-05-27),

15. 6534037 - Non-steroidal compounds for steroid receptors and uses relating thereto (2003-03-18),

Company Overview

Neorx Corporation, based in Seattle, WA, specializes in the development of radiolabeled therapeutics aimed at addressing various medical conditions, particularly in the realm of cardiovascular pathologies. The company focuses on innovative technologies such as radiolabeled annexins and radionuclide complexes, which facilitate targeted therapy and diagnostics. Their expertise extends to creating protein-diagnostic conjugates and therapeutic inhibitors, utilizing advanced pretreatment methods and biotin-DOTA conjugates to enhance treatment efficacy.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

156 Patents

#15 in Seattle, WA

#50 in Washington

#2,544 in US

#5,265 in the World

Seattle, WA, United States of America

Neorx Corporation

Forward Citations = 6,558

69 inventors:

Alan R Fritzberg (44 out of 53 patents)

Sudhakar Kasina (38 out of 50 patents)

John M Reno (36 out of 45 patents)

4. Ananthachari Srinivasan (33 out of 48 patents)

5. David John Grainger (20 out of 42 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Neorx Corporation. Retrieved from https://idiyas.com/company/neorx

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…